Quantification of Acid Ceramidase Inhibitor (ARN) in Rat Plasma Using LC-MS/MS and its Application for Pharmacokinetic Studies
Mentor 1
Shama Mirza
Location
Union Wisconsin Room
Start Date
5-4-2019 1:30 PM
End Date
5-4-2019 3:30 PM
Description
Glioblastoma (GBM) is the most common malignant primary cancer of the central nervous system. Despite the conventional therapy, life expectancy is less than two years. GBM is a spontaneous tumor formed mainly in the brain, usually characterized by infiltrating cell growth, and able to form in two ways; ninety percent develop from normal glial cells by multistep tumorigenesis (primary), while the other ten percent are from low grade tumors (secondary). Thus far, treatments are limited. Due to its high proliferative activity, it is capable of infiltrating surrounding tissues, which makes it difficult to completely resect, even with MRI or CT guidance. Previous studies on our lab showed promise in inhibiting acid ceramidase as a potential therapeutic regime to kill GBM cells. Thus, we are testing acid ceramidase inhibitors as potential drugs for the treatment of GBM with efficacy. The goal of this study is to develop a simple, specific and reliable LC-MS/MS method for quantifying and analyzing the pharmacokinetics properties of acid ceramidase inhibitor (ARN) in rat plasma. This work will provide further understanding of ARN metabolism and disposition in-vivo and also validating the method for quantitative determination of ARN in rat plasma. This research opens up more knowledge on a possible drug for GBM towards widening alternative treatments for this disease.
Quantification of Acid Ceramidase Inhibitor (ARN) in Rat Plasma Using LC-MS/MS and its Application for Pharmacokinetic Studies
Union Wisconsin Room
Glioblastoma (GBM) is the most common malignant primary cancer of the central nervous system. Despite the conventional therapy, life expectancy is less than two years. GBM is a spontaneous tumor formed mainly in the brain, usually characterized by infiltrating cell growth, and able to form in two ways; ninety percent develop from normal glial cells by multistep tumorigenesis (primary), while the other ten percent are from low grade tumors (secondary). Thus far, treatments are limited. Due to its high proliferative activity, it is capable of infiltrating surrounding tissues, which makes it difficult to completely resect, even with MRI or CT guidance. Previous studies on our lab showed promise in inhibiting acid ceramidase as a potential therapeutic regime to kill GBM cells. Thus, we are testing acid ceramidase inhibitors as potential drugs for the treatment of GBM with efficacy. The goal of this study is to develop a simple, specific and reliable LC-MS/MS method for quantifying and analyzing the pharmacokinetics properties of acid ceramidase inhibitor (ARN) in rat plasma. This work will provide further understanding of ARN metabolism and disposition in-vivo and also validating the method for quantitative determination of ARN in rat plasma. This research opens up more knowledge on a possible drug for GBM towards widening alternative treatments for this disease.
